Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Non-Current Assets (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Non-Current Assets for 3 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 4.92% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, down 4.92% year-over-year, with the annual reading at $14.5 million for FY2025, 4.92% down from the prior year.
  • Non-Current Assets hit $14.5 million in Q4 2025 for Mangoceuticals, down from $15.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $21.6 million in Q1 2025 to a low of $211639.0 in Q1 2024.
  • Historically, Non-Current Assets has averaged $9.9 million across 3 years, with a median of $14.6 million in 2024.
  • Biggest five-year swings in Non-Current Assets: dropped 27.72% in 2024 and later skyrocketed 10095.29% in 2025.
  • Year by year, Non-Current Assets stood at $215391.0 in 2023, then soared by 7001.0% to $15.3 million in 2024, then decreased by 4.92% to $14.5 million in 2025.
  • Business Quant data shows Non-Current Assets for MGRX at $14.5 million in Q4 2025, $15.9 million in Q3 2025, and $20.7 million in Q2 2025.